Company intelligence / Profile preview
Pharmahungary Group
Budapest, Budapest, Hungarypharmahungary.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Commercial
01
Overview
Pharmahungary Group has over 20 years of experience with more than 300 development projects. It offers innovative preclinical and clinical R&D services focused on cardiovascular and metabolic indications. The company develops novel diagnostics and therapeutics—especially miRNA-based drugs—and provides full CRO/CMO services from cell models to large animal studies. Several in-house R&D programs are available for outlicensing or co-development.
- Therapeutic areas
- ImmunologyCardiovascularMetabolic DisordersNephrology
- Modalities
- Small moleculeBiologicOligonucleotide (miRNA therapeutics)Advanced Therapy Medicinal Products (ATMPs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
none specified publicly as of June 2025—open to co-development/outlicensing partnerships
Beyond the preview
Go deeper on Pharmahungary Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmahungary Group.